Biodesix Dirección
Dirección controles de criterios 2/4
El CEO de Biodesix es Scott Hutton , nombrado en Jan 2020, tiene una permanencia de 6.33 años. compensación anual total es $2.24M, compuesta por 28.7% salario y 71.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.48% de las acciones de la empresa, por valor de $728.09K. La antigüedad media del equipo directivo y de la junta directiva es de 6 años y 6.2 años, respectivamente.
Información clave
Scott Hutton
Chief Executive Officer (CEO)
US$2.2m
Compensación total
| Porcentaje del salario del CEO | 28.74% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 6yrs |
| Promedio de permanencia en la Junta Directiva | 6.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.
Actualización de narrativa • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.Actualización de narrativa • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.
Actualización de narrativa • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.Actualización de narrativa • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.Actualización de narrativa • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).Actualización de narrativa • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).Actualización de narrativa • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).Artículo de análisis • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...Actualización de narrativa • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).Actualización de narrativa • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.Artículo de análisis • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Artículo de análisis • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...Artículo de análisis • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...Actualización de narrativa • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.Artículo de análisis • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...Artículo de análisis • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...Artículo de análisis • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...Artículo de análisis • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...Artículo de análisis • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
Nueva narrativa • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.Artículo de análisis • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...Artículo de análisis • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Artículo de análisis • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...Artículo de análisis • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Artículo de análisis • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...Artículo de análisis • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...Artículo de análisis • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$32m |
| Dec 31 2025 | US$2m | US$643k | -US$35m |
| Sep 30 2025 | n/a | n/a | -US$40m |
| Jun 30 2025 | n/a | n/a | -US$41m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$2m | US$589k | -US$43m |
| Sep 30 2024 | n/a | n/a | -US$44m |
| Jun 30 2024 | n/a | n/a | -US$45m |
| Mar 31 2024 | n/a | n/a | -US$47m |
| Dec 31 2023 | US$2m | US$515k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$66m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$3m | US$515k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$5m | US$490k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$2m | US$364k | -US$31m |
| Sep 30 2020 | n/a | n/a | -US$33m |
| Jun 30 2020 | n/a | n/a | -US$34m |
| Mar 31 2020 | n/a | n/a | -US$33m |
| Dec 31 2019 | US$337k | US$298k | -US$31m |
Compensación vs. Mercado: La compensación total de Scott($USD2.24M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.66M).
Compensación vs. Ingresos: La compensación de Scott ha aumentado mientras la empresa no es rentable.
CEO
Scott Hutton (53 yo)
6.3yrs
Permanencia
US$2,238,470
Compensación
Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.3yrs | US$2.24m | 0.48% $ 728.1k | |
| CFO, Secretary & Treasurer | 9.1yrs | US$962.00k | 0.16% $ 242.3k | |
| Chief Commercial Officer | 8.3yrs | US$1.01m | 0.097% $ 146.6k | |
| Founder & CTO | no data | sin datos | sin datos | |
| Chief Scientific Officer | less than a year | sin datos | 0.10% $ 154.7k | |
| Senior Director of Human Resources | 2.3yrs | sin datos | sin datos | |
| Chief Growth Officer | 6.2yrs | sin datos | sin datos | |
| Co-Chief Medical Officer | no data | sin datos | sin datos | |
| Co-Chief Medical Officer | 6yrs | sin datos | sin datos | |
| Head of Radiomics | 1.3yrs | sin datos | sin datos | |
| VP & Controller | 5.3yrs | sin datos | 0.016% $ 23.7k |
6.0yrs
Permanencia media
50yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BDSX es experimentado (6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.3yrs | US$2.24m | 0.48% $ 728.1k | |
| Independent Chairman | 17.9yrs | US$26.87k | 0.25% $ 377.9k | |
| Independent Director | 17.9yrs | sin datos | 22.88% $ 34.5m | |
| Independent Director | 5.8yrs | US$31.71k | 0.18% $ 271.4k | |
| Independent Director | 3.3yrs | US$26.87k | 12.59% $ 19.0m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 14.3yrs | US$30.10k | 1.51% $ 2.3m | |
| Independent Director | 4.4yrs | US$26.87k | 0.18% $ 266.9k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6.1yrs | US$33.32k | 0.053% $ 80.7k |
6.2yrs
Permanencia media
62.5yo
Promedio de edad
Junta con experiencia: La junta directiva de BDSX se considera experimentada (6.2 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/24 11:42 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Biodesix, Inc. está cubierta por 8 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |